| 期 |
栏目 |
标题 |
文件 |
| 卷 84, 编号 2 (2012) |
Editorial |
Impairment of intestinal mucosa composition in mechanisms of intestinal dysfunction development in patients with hepatic cirrhosis |
|
| 卷 88, 编号 2 (2016) |
Editorial |
Current principles in the screening, diagnosis, and therapy of colorectal cancer |
(Rus)
|
| 卷 88, 编号 8 (2016) |
Editorial |
Long-term infliximab therapy for ulcerative colitis in real clinical practice |
(Rus)
|
| 卷 89, 编号 2 (2017) |
Editorial |
Efficacy of adalimumab for Crohn’s disease in real clinical practice |
(Rus)
|
| 卷 90, 编号 3 (2018) |
Editorial |
Stem Cell Therapy for Perianal Crohn’s Disease |
(Rus)
|
| 卷 90, 编号 6 (2018) |
Editorial |
Efficacy and tolerability of certolizumab pegol in Crohn's disease in clinical practice |
(Rus)
|
| 卷 90, 编号 2 (2018) |
Editorial |
Personalized medicine in the treatment of inflammatory bowel diseases |
(Rus)
|
| 卷 90, 编号 2 (2018) |
Editorial |
Mesenchymal stromal cells of bone marrow and azathioprine in Crohn's disease therapy |
(Rus)
|
| 卷 90, 编号 12 (2018) |
Editorial |
Adherence to therapy of patients with inflammatory bowel diseases |
(Rus)
|
| 卷 90, 编号 11 (2018) |
Editorial |
Clostridium difficile in inflammatory bowel disease |
(Rus)
|
| 卷 91, 编号 4 (2019) |
Editorial |
O.V. Knyazev, A.V. Kagramanova, I.A. Korneeva, K.K. Noskova, S.V. Belousov, A.I. Parfenov |
(Rus)
|
| 卷 91, 编号 8 (2019) |
Editorial |
Evaluation of efficacy and comparative frequency of adverse events in patients with ulcerative colitis receiving the original infliximab and its biosimilar. One year of observation |
(Rus)
|
